Navigation Links
Cytos Biotechnology Ltd Reports Second Quarter 2013 Financial Results and Recent Developments
Date:8/5/2013

ZURICH, August 6, 2013 /PRNewswire/ --

  • Global Phase 2b clinical trial with CYT003 progressing as planned
  • Development team for CYT003 strengthened
  • A*Star and Cytos bring Singapore's first influenza vaccine to clinical testing
  • All agenda items approved at the Annual Shareholders' Meeting

Cytos Biotechnology Ltd. ("Cytos" or the "Company") announced today its financial results and business highlights for the quarter ended June 30, 2013.

Highlights

The Phase 2b clinical trial with Cytos' lead product candidate CYT003 in allergic asthma is progressing as planned. The clinical trial is enrolling patients at more than ninety centers, in eight countries, in the United States and Europe. Approximately 360 adult patients with moderate to severe allergic asthma, not sufficiently controlled on current standard inhaled corticosteroid (ICS +/- LABA) therapy, will be treated in this study. Enrolment is expected to be completed by year-end 2013. Top-line data are planned for Q2 2014. Upon completion of enrolment, Cytos can call the second tranche of the convertible loan notes and will be receiving a payment of CHF 6.625 million.

The development team for CYT003 has been further strengthened with the hire of Dr. Dorothee Krumwieh, who joined Cytos in May 2013 as Vice President and Program Leader for CYT003. Prior to joining Cytos, Dr. Krumwieh was in charge of the neurological development programs at Merck Serono. Previously, Dr. Krumwieh held various positions in research and regulatory affairs and lead cross functional development programs in oncology and dermatology at Merck Serono, Serono and Behringwerke AG. Dorothee Krumwieh received a PhD in immunology from the University of Freiburg im Breisgau, Germany.

On May 17, 2013, Cytos announced that A*STAR and Cytos brought Singapore's first influenza vaccine to clinical testing. The first healthy subject was dosed in a Phase 1 clinical trial with the H1N1 influenza vaccine candidate based on Cytos' proprietary bacteriophage Qbeta virus-like particle (VLP) technology.

At the Annual Shareholders' Meeting, held on June 28, 2013, all agenda items were approved by the shareholders, including the extension of the authorized capital until June 27, 2015, as well as the re-election of Dr. Christian Itin and Kurt von Emster as members of the Board of Directors.

Financial Results

Three-month period from April 1 to June 30, 2013

On June 30, 2013, funds available for financing the operations (including cash, cash equivalents and trade and other receivables) amounted to CHF 18.1 million. The funds were CHF 5.5 million less than on March 31, 2013, primarily due to expenses incurred in on-going operating activities.

On June 30, 2013, the nominal value of convertible bonds not held by the Company amounted to CHF 13.17 million. Cytos did not buy back any convertible bonds on the market during the second quarter of 2013.

The nominal value of the secured convertible loan notes (first tranche) is CHF 6.625 million. Upon completion of enrolment in the ongoing Phase 2b clinical trial with CYT003 in allergic asthma, the Company can call the second tranche of CHF 6.625 million, which is expected to happen towards the end of this year.

Revenue comprising deferred income from license fees paid by Novartis of CHF 0.25 million has been recognized in the second quarter 2013, unchanged from the second quarter 2012.

Financial summary (IFRS, consolidated)

(in CHF million) Q2 2013 Q2 2012 Revenue 0.3 0.4 Net operating cost (6.5) (2.2) Operating loss (6.3) (1.8) Net loss (8.1) (2.6) Net loss per share (in CHF) (0.36) (0.27) (in CHF million) 30.6.2013 31.3.2013 Cash, cash equivalents & trade and other receivables 18.1 23.6 Full-time equivalents 24.5 22.5

The detailed Q2 Financial Report 2013 can be downloaded at:

http://www.cytos.com/uploads/2013/CytosQ22013EN.pdf

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company focused on the development of targeted immuno-therapies. The Company's lead product candidate CYT003 is a novel, first-in-class, immune modulator in Phase 2 clinical development as a potential new treatment for asthma.

CYT003 has a novel mechanism of action that inhibits the immune response that causes asthma, and may therefore be beneficial for the control of asthma. In a successfully completed Phase 2a study, CYT003 was shown to maintain asthma control and lung function in patients with persistent allergic asthma despite withdrawal of standard therapy with inhaled corticosteroids. CYT003 has been shown to have a good safety and tolerability profile in more than 450 individuals receiving the active agent so far.

Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich. It is located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.

http://www.cytos.com 

This foregoing press release may contain forward-looking statements that include words or phrases such as "would", "can", "expect", "are intended for", "are designed to", or other similar expressions. These forward-looking statements are subject to a variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those presented. There can be no assurance that any further therapeutic entities will enter clinical trials, that clinical trial results will be predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will be marketed successfully. Against the background of these uncertainties readers should not rely on forward-looking statements. The Company assumes no responsibility to update forward-looking statements or adapt them to future events or developments.


'/>"/>
SOURCE Cytos Biotechnology Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cytos Invites to the Annual Shareholders Meeting 2013
2. A*STAR and Cytos Bring Singapores First Influenza Vaccine to Clinical Testing
3. Cytos VLP Platform is Basis for Phase 1 Clinical Trial with Anti-IgE Vaccine
4. CytoSorbents Receives Approximately $400,000 in Non-Dilutive Capital from the Sale of Net Operating Loss Carryovers
5. Cytos Biotechnology Ltd Reports Third Quarter 2012 Financial Results, Recent Development and Outlook
6. The Galien Foundation Announces 2013 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology"
7. ResearchMoz.us: Biotechnology Market By Application (Biopharmacy, Bioservices, Bioagri, Bioindustrial), By Technology (Fermentation, Tissue Regeneration, PCR, Nanobiotechnology, DNA Sequencing & Others) - Global Industry Analysis, Size, Share, Growt
8. Platine Pharma Services et Indicia Biotechnology se rapprochent pour renforcer leur leadership en immunomonitoring
9. Goodwin Biotechnology Announces Process Development Sub-Contract for an Anthrax Vaccine
10. Sony Biotechnology Inc.s New Technology for Science Provides Researchers Results in Color
11. Plandai Biotechnology, Inc. Announces Formation Of New Entity To Develop Pharmaceutical Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... 2017 NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical collaboration agreement with the Children,s Hospital of ... M.D., a US key opinion leader in the mitochondrial medicine ... ... from NeuroVive,s research program, NVP015, in certain experimental disease models. ...
(Date:1/21/2017)... Research and Markets has announced the addition of ... Test (Tumor, Clinical Chemistry, Microbiology, Esoteric), By Type of Lab ... Cancer, HIV/AIDS etc.), Forecast to 2022" report to their ... ... especially clinical lab testing, which has evolved as a major ...
(Date:1/21/2017)... CAMBRIDGE, Mass. , Jan. 20, 2017 ... the Keystone Symposia Conference, "PI3K Pathways in ... Pharmaceuticals, Inc. (NASDAQ: INFI ... oral immuno-oncology development candidate that selectively inhibits ... is able to help overcome resistance to ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... ... institution’s inaugural K-20 Education Summit to be held March 23-25, 2017 in Tampa, ... Jan. 25, 2017. , The keynote speakers include Dr. Michelle R. Weise, executive ...
(Date:1/23/2017)... ... ... Wooden and plastic balance boards have been around since at least the 1950s and are ... the first and only balance board to use a patent-pending design featuring high-pressure inflation technology ... time as well as skill-level adjustable for all ages and abilities. The board can ...
(Date:1/23/2017)... SC (PRWEB) , ... January 23, 2017 , ... ... is the premiere organization in North America for the scientific development, healthcare training ... 2017 Annual Scientific Session, and its 2017 AAT Member Certification Qualification Courses for ...
(Date:1/23/2017)... ... January 23, 2017 , ... Moisture ... choosing the right method is paramount to success. Selecting an inappropriate measurement method ... where multiple persons use the same equipment. Rare or expensive substances are wasted ...
(Date:1/23/2017)... ... January 23, 2017 , ... Old School Labs™, makers ... Mr. Olympia Classic Physique bodybuilder Breon Ansley to its growing team of brand ambassadors. ... bodybuilder in 2012 and in less than a year was able to turn professional, ...
Breaking Medicine News(10 mins):